Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.
Immunotherapy
Melanoma
Metagenome
Metatranscriptome
Microbiome
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
09 10 2019
09 10 2019
Historique:
received:
23
05
2019
accepted:
12
09
2019
entrez:
11
10
2019
pubmed:
11
10
2019
medline:
9
4
2020
Statut:
epublish
Résumé
Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expression of metagenomic functions in the microbial community. In melanoma patients undergoing immunotherapy, gut microbiome was characterized in pre-treatment stool using 16S rRNA gene and shotgun metagenome sequencing (n = 27). Transcriptional expression of metagenomic pathways was confirmed with metatranscriptome sequencing in a subset of 17. We examined associations of taxa and metagenomic pathways with progression-free survival (PFS) using 500 × 10-fold cross-validated elastic-net penalized Cox regression. Higher microbial community richness was associated with longer PFS in 16S and shotgun data (p < 0.05). Clustering based on overall microbiome composition divided patients into three groups with differing PFS; the low-risk group had 99% lower risk of progression than the high-risk group at any time during follow-up (p = 0.002). Among the species selected in regression, abundance of Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta were related to shorter PFS, and Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA to longer PFS. Metagenomic functions related to PFS that had correlated metatranscriptomic expression included risk-associated pathways of L-rhamnose degradation, guanosine nucleotide biosynthesis, and B vitamin biosynthesis. This work adds to the growing evidence that gut microbiota are related to immunotherapy outcomes, and identifies, for the first time, transcriptionally expressed metagenomic pathways related to PFS. Further research is warranted on microbial therapeutic targets to improve immunotherapy outcomes.
Sections du résumé
BACKGROUND
Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expression of metagenomic functions in the microbial community.
METHODS
In melanoma patients undergoing immunotherapy, gut microbiome was characterized in pre-treatment stool using 16S rRNA gene and shotgun metagenome sequencing (n = 27). Transcriptional expression of metagenomic pathways was confirmed with metatranscriptome sequencing in a subset of 17. We examined associations of taxa and metagenomic pathways with progression-free survival (PFS) using 500 × 10-fold cross-validated elastic-net penalized Cox regression.
RESULTS
Higher microbial community richness was associated with longer PFS in 16S and shotgun data (p < 0.05). Clustering based on overall microbiome composition divided patients into three groups with differing PFS; the low-risk group had 99% lower risk of progression than the high-risk group at any time during follow-up (p = 0.002). Among the species selected in regression, abundance of Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta were related to shorter PFS, and Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA to longer PFS. Metagenomic functions related to PFS that had correlated metatranscriptomic expression included risk-associated pathways of L-rhamnose degradation, guanosine nucleotide biosynthesis, and B vitamin biosynthesis.
CONCLUSIONS
This work adds to the growing evidence that gut microbiota are related to immunotherapy outcomes, and identifies, for the first time, transcriptionally expressed metagenomic pathways related to PFS. Further research is warranted on microbial therapeutic targets to improve immunotherapy outcomes.
Identifiants
pubmed: 31597568
doi: 10.1186/s13073-019-0672-4
pii: 10.1186/s13073-019-0672-4
pmc: PMC6785875
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Subventions
Organisme : NCI NIH HHS
ID : R01 CA159036
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA225450
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA164964
Pays : United States
Organisme : NCI NIH HHS
ID : P50CA225450
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA164964
Pays : United States
Références
Nat Methods. 2012 Jun 10;9(8):811-4
pubmed: 22688413
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
ISME J. 2012 Aug;6(8):1621-4
pubmed: 22402401
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
PLoS Comput Biol. 2015 May 07;11(5):e1004226
pubmed: 25950956
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4516-22
pubmed: 20534432
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
BMC Genomics. 2018 Mar 20;19(1):210
pubmed: 29558893
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
mSystems. 2017 Mar 7;2(2):
pubmed: 28289731
J Clin Invest. 2013 Sep;123(9):3685-92
pubmed: 23999443
EBioMedicine. 2014 Dec 1;1(2-3):167-172
pubmed: 25601913
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
Genome Med. 2019 Oct 9;11(1):61
pubmed: 31597568
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Glycoconj J. 1994 Dec;11(6):527-32
pubmed: 7696855
Bioinformatics. 2007 May 15;23(10):1282-8
pubmed: 17379688
Microbiome. 2014 May 05;2:15
pubmed: 24910773
Cell. 2016 Apr 7;165(2):276-87
pubmed: 27058662
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):731-740
pubmed: 30733306
Immunology. 2018 Apr;153(4):415-422
pubmed: 29164593
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Nucleic Acids Res. 2016 Jan 4;44(D1):D471-80
pubmed: 26527732
Eur J Hum Genet. 2017 Jun;25(7):854-862
pubmed: 28594416
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Science. 2012 Jun 8;336(6086):1268-73
pubmed: 22674334
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Nat Methods. 2013 Jan;10(1):57-9
pubmed: 23202435
Ann Oncol. 2017 Jun 01;28(6):1368-1379
pubmed: 28368458
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
ISME J. 2011 Feb;5(2):169-72
pubmed: 20827291
Microbiome. 2017 Feb 8;5(1):17
pubmed: 28179014
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Neoplasia. 2017 Oct;19(10):848-855
pubmed: 28923537
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
PLoS Comput Biol. 2009 Aug;5(8):e1000465
pubmed: 19680427
Mol Biol Evol. 2009 Jul;26(7):1641-50
pubmed: 19377059